Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector

GA O'Hara, CJA Duncan, KJ Ewer… - Journal of Infectious …, 2012 - academic.oup.com
GA O'Hara, CJA Duncan, KJ Ewer, KA Collins, SC Elias, FD Halstead, AL Goodman…
Journal of Infectious Diseases, 2012academic.oup.com
Background. Vaccine development in human Plasmodium falciparum malaria has been
hampered by the exceptionally high levels of CD8+ T cells required for efficacy. Use of
potently immunogenic human adenoviruses as vaccine vectors could overcome this
problem, but these are limited by preexisting immunity to human adenoviruses. Methods.
From 2007 to 2010, we undertook a phase I dose and route finding study of a new malaria
vaccine, a replication-incompetent chimpanzee adenovirus 63 (ChAd63) encoding the …
Abstract
Background.  Vaccine development in human Plasmodium falciparum malaria has been hampered by the exceptionally high levels of CD8+ T cells required for efficacy. Use of potently immunogenic human adenoviruses as vaccine vectors could overcome this problem, but these are limited by preexisting immunity to human adenoviruses.
Methods.  From 2007 to 2010, we undertook a phase I dose and route finding study of a new malaria vaccine, a replication-incompetent chimpanzee adenovirus 63 (ChAd63) encoding the preerythrocytic insert multiple epitope thrombospondin-related adhesion protein (ME-TRAP; n = 54 vaccinees) administered alone (n = 28) or with a modified vaccinia virus Ankara (MVA) ME-TRAP booster immunization 8 weeks later (n = 26). We observed an excellent safety profile. High levels of TRAP antigen–specific CD8+ and CD4+ T cells, as detected by interferon γ enzyme-linked immunospot assay and flow cytometry, were induced by intramuscular ChAd63 ME-TRAP immunization at doses of 5 × 1010 viral particles and above. Subsequent administration of MVA ME-TRAP boosted responses to exceptionally high levels, and responses were maintained for up to 30 months postvaccination.
Conclusions.  The ChAd63 chimpanzee adenovirus vector appears safe and highly immunogenic, providing a viable alternative to human adenoviruses as vaccine vectors for human use.
Clinical Trials Registration.  NCT00890019.
Oxford University Press